The Europe Digital Diabetes Management Market would witness market growth of 11.7% CAGR during the forecast period (2022-2028).
In recent years, technological advancements have created highly inventive tools for people to track their health. The FreeStyle Libre flash glucose monitor, a disk-like sensor implanted into the upper arm and worn there for up to 14 days, was authorized by the FDA in 2017. A reader can be passed over the sensor after it has been implanted, providing real-time glucose levels, trends, and even warnings for critically low or high glucose levels in some models of the monitor.
Patients who get insulin on a regular basis are at a higher risk of hypoglycemia. Glucagon kits may be given to those who have been prescribed insulin as a preventative strategy. The Lilly Glucagon Mobile App was designed and launched by Eli Lilly to educate users on how to properly give glucagon, provide frequent reminders about practicing and preparing glucagon administration, and contain pharmacological safety information and indications. Since glucagon is only used in emergencies, this app might be useful for reminding patients and their caretakers how to administer it safely if the need arises.
The European Commission has acknowledged the rising market for digital health. It issued recommendations on the qualification and categorization of stand-alone software used in the healthcare sector as a medical device in 2012 (updated in 2016). Mobile apps are deemed medical devices under this guidance if they are used "primarily for diagnostic and/or therapeutic purposes," such as disease diagnosis, prevention, monitoring, treatment, or relief. In the European Region, around 60 million individuals have diabetes, accounting for 10.3 percent of men and 9.6 percent of women aged 25 and up.
The Germany market dominated the Europe Digital Diabetes Management Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,975.7 million by 2028. The UK market is experiencing a CAGR of 10.8% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 12.6% during (2022 - 2028).
Based on Type, the market is segmented into Wearables and Handheld Devices. Based on Product & Service, the market is segmented into Devices (Continuous Glucose Monitoring (CGM) Systems, Smart Glucose Meters, Smart Insulin Pens, and Smart Insulin Pumps/Closed-loop Pumps & Smart Insulin Patches), Application (Diabetes & Blood Glucose Tracking Apps and Obesity & Diet Management Apps), Data Management Software & Platforms, and Services. Based on End User, the market is segmented into Self/Home Healthcare, Hospitals & Specialty Diabetes Clinics, and Academic & Research Institutes. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Digital Diabetes Management Market will Hit $29.5 Billion by 2028, at a CAGR of 12%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Abbott Laboratories, Terumo Corporation, F. Hoffmann-La Roche Ltd., DexCom, Inc., Novo Nordisk A/S, ACON Laboratories, Inc., Bayer AG, B. Braun Melsungen AG, and Azumio, Inc.
By Type
By Product & Service
By End User
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 